Gocatamig clinical trials
Also written HPN328 and MK-6070.
How each study uses gocatamig has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the gocatamig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Merck Sharp & Dohme LLC (3) · Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses gocatamig has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07227597Written as GocatamigReport a problem
- A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)Not yet recruitingPhase 3Merck Sharp & Dohme LLCNCT07908537Written as GocatamigReport a problem
- A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06780137Written as GocatamigReport a problem
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Active, not recruitingPhase 1/2Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT04471727Written as GocatamigReport a problem
Tested with established drugs · 2 — they are given beside it
- A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)Not yet recruitingPhase 3Merck Sharp & Dohme LLCNCT07908537Written as GocatamigReport a problem
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Active, not recruitingPhase 1/2Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT04471727Written as GocatamigReport a problem
Tested in a combination · 2 — another drug in the study is under test too
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07227597Written as GocatamigReport a problem
- A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06780137Written as GocatamigReport a problem
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call gocatamig · ClinicalTrials.gg INT018090
- UNII (FDA) U6CKL88C8HGOCATAMIGOne source FDA
- NCI Thesaurus C175947GocatamigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U6CKL88C8H | GOCATAMIG | One source FDA |
| NCI Thesaurus | C175947 | Gocatamig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.